Estimated Prevalence and Economic Burden of Severe, Uncontrolled Asthma in the United States

Cyclic AMP in dendritic cells: A novel potential target for disease‐modifying agents in asthma and other allergic disorders

“…These patients have a decreased quality of life (Global Initiative for Asthma, 2019). Among asthma patients, 2.5%–5% of all asthma patients have severe, uncontrolled disease, but this population accounts for ~38% of asthma‐related direct costs, representing an unmet medical need (Hankin, Bronstone, Wang, Small, & Buck, 2013; Yaghoubi, Adibi, Safari, FitzGerald, & Sadatsafavi, 2019).…”

“…have uncontrolled asthma with poor symptom control and/or frequent exacerbations (Centers for DiseaseControl and Prevention, 2014).These patients have a decreased quality of life (Global Initiative for Asthma, 2019). Among asthma patients, 2.5%-5% of all asthma patients have severe, uncontrolled disease, but this population accounts for 38% of asthma-related direct costs, representing an unmet medical need(Hankin, Bronstone, Wang, Small, & Buck, 2013;Yaghoubi, Adibi, Safari, FitzGerald, & Sadatsafavi, 2019).Asthma is defined by its symptoms and signs (breathlessness, chronic airway inflammation, and airway hyperresponsiveness), and not by its aetiology. Current therapies for asthma focus on symptomatic treatment (e.g.…”

Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials

“…3 Indeed, people with severe asthma have an increased likelihood of experiencing asthma exacerbations and poor health-related quality of life, are at increased risk of becoming dependent on oral corticosteroids (OCS) for disease control, 2 and (if their disease is uncontrolled) consume the majority of asthma-related healthcare resources. [3][4][5] In animal models, multiple studies have demonstrated that interleukin-13 (IL-13), a type-2 pleiotropic cytokine, can induce airway hyperresponsiveness, goblet cell metaplasia, and lung eosinophilia, which contribute to the pathophysiology of asthma. 6,7 IL-13 has also been demonstrated to contribute to airway remodelling via transforming growth factor (TGF)-βmediated collagen deposition.…”

Mapping geographic variability of severe uncontrolled asthma in the United States

“…10 Approximately 5% to 10% of patients with asthma have SA, 8,[11][12][13] and 20% to 50% of those patients have severe uncontrolled asthma (SUA) due to exacerbations requiring hospitalizations, emergency department visits, and/or systemic corticosteroids (SCS). [11][12][13] The TENOR study revealed 83% of patients with severe or difficult-to-treat disease had UA. 14 The CHOICE study found that only 14.3% of patients were well-controlled.…”